MARKET

CRBP

CRBP

Corbus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.405
-0.075
-3.02%
Opening 14:12 02/25 EST
OPEN
2.460
PREV CLOSE
2.480
HIGH
2.550
LOW
2.280
VOLUME
8.19M
TURNOVER
--
52 WEEK HIGH
9.78
52 WEEK LOW
0.9100
MARKET CAP
202.11M
P/E (TTM)
-1.3504
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Corbus Pharmaceuticals Holdings Inc. stock falls Wednesday, underperforms market
Shares of Corbus Pharmaceuticals Holdings Inc. slipped 1.98% to $2.48 Wednesday, on what proved to be an all-around great trading session for the stock...
marketwatch.com · 21h ago
Making A List Of Penny Stocks To Watch This Week? 4 To Know
Feb 24, 2021 (Penny Stocks via COMTEX) -- Looking For Penny Stocks to Watch? Check Out These 4 While February has not been the best month for blue-chip...
Penny Stocks · 22h ago
5 Hot Penny Stocks Analysts Rate A Buy Right Now But Do You Agree?
Feb 24, 2021 (Penny Stocks via COMTEX) -- Hot Penny Stocks To Buy According To These Analysts Are you looking for penny stocks to buy right now? You're not...
Penny Stocks · 22h ago
Hot Marijuana Penny Stocks You Might've Missed In February 2021
Penny Stocks · 22h ago
Hot Penny Stocks to Watch Today If You Like Marijuana Stocks
Feb 24, 2021 (Penny Stocks via COMTEX) -- Marijuana Stocks Are Heating Up The Stock Market Today We know the exotic nature of certain industries, especially...
Penny Stocks · 22h ago
4 Penny Stocks To Watch For February 2021 Especially If You Like Biotech
Feb 24, 2021 (Penny Stocks via COMTEX) -- Will These Biotech Penny Stocks Continue to See Bullish Momentum? In the past twelve months, biotech penny stocks...
Penny Stocks · 22h ago
Could These 4 Biotech Stocks See A Short Squeeze This Week?
Feb 24, 2021 (StockMarket.com via COMTEX) -- Will These Biotech Stocks Continue To Exhibit Bullish Momentum? GameStop (NYSE: GME) has become the name on the...
StockMarket.com · 22h ago
Cannabis Stock Gainers And Losers From February 23, 2021
GAINERS: Rhinomed (OTCQB: RHNMF) shares closed up 19.94% at $0.10
Benzinga · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRBP. Analyze the recent business situations of Corbus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRBP stock price target is 1.880 with a high estimate of 3.000 and a low estimate of 1.220.
EPS
Institutional Holdings
Institutions: 222
Institutional Holdings: 40.57M
% Owned: 48.28%
Shares Outstanding: 84.04M
TypeInstitutionsShares
Increased
21
7.24M
New
55
-3.60M
Decreased
42
20.84M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.69%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Independent Director
Alan Holmer
Chief Executive Officer/Director
Yuval Cohen
Chief Financial Officer
Sean Moran
Other
Craig Millian
Executive Director
Sergei Atamas
Other
Barbara White
Independent Director
Avery Catlin
Independent Director
Rachelle Jacques
Independent Director
John Jenkins
Independent Director
Peter Salzmann
  • Dividends
  • Splits
  • Insider Activity
No Data
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Webull offers kinds of Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ:CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.